Broadened CDMO Business Will Cover Commercial New Drugs As Well As in Development Stage of Ones
- Broadened CDMO Business Will Cover Commercial New Drugs As Well As in Development Stage of Ones -
TOKYO, July 12, 2018 /PRNewswire/ -- AGC Inc., a world-leading manufacturer of glass, chemicals and high-tech materials, announced on July 12 a major expansion of facilities at its Chiba Plant that will result in an approximately tenfold increase in the company’s GMP(*1)-compliant synthetic pharmaceutical intermediate and active ingredient (*2) production capacity. The new capacity is set to come online in October 2019.
AGC began developing and manufacturing pharmaceutical and agrochemical intermediates and active ingredients on a contract basis in the 1980s. Leveraging its edge in fluorine technologies and extensive experience in in-house drug discovery and other fields, AGC now offers a range of CDMO (*3) services tailored to customer needs.
While AGC has to date mainly provided CDMO services for in the development stage of new drugs, this expansion will give AGC the end-to-end capability to produce commercial drugs too, allowing it to deliver more advanced one-stop solutions. The new facilities will also be capable of producing hard-to-handle active ingredients, such as the highly potent active pharmaceutical ingredients typically used in cancer therapy. AGC will therefore be able to meet a wider
range of customer demand.
The AGC Group’s “AGC plus” management policy identifies the life sciences as one of its strategic businesses. Moving forward, the group will continue to invest in the capacity needed to meet ongoing growth in demand for pharmaceutical intermediate and active ingredient CDMO services.
(*1) GMP: Good manufacturing practice (standards governing the production and quality control of pharmaceutical products and quasi-drugs).
(*2) Synthetic pharmaceutical intermediates and active ingredients: Intermediates and active ingredients for pharmaceutical products that are produced by chemical synthesis.
(*3) CDMO: Contract development and manufacturing organization (a company that develops production methods and manufactures products for another company on a contract basis).
For more information, please visit: https://kyodonewsprwire.jp/attach/201807095798-O1-vIa55jNK.pdf
About the AGC Group
AGC Inc. (Headquarters: Tokyo, President & CEO: Takuya Shimamura) is the parent company of the AGC Group, a world-leading glass solution provider and supplier of flat, automotive and display glass, chemicals, ceramics and other high-tech materials and components. Based on more than a century of technical innovation, the AGC Group has developed a wide range of cutting-edge products. The AGC Group employs some 50,000 people worldwide and generates annual sales of approximately 1.5 trillion Japanese yen through business in about 30 countries. For more information, please visit: http://www.agc.com/en/.
* The company changed its name from Asahi Glass Co., Ltd. to AGC Inc. on July 1, 2018.
View original content:http://www.prnewswire.com/news-releases/agc-to-expand-gmp-compliant-synthetic-pharmaceutical-intermediate-and-active-ingredient-production-capacity-tenfold-300679858.html
SOURCE AGC Inc.
